Osteoporosis

The FDA has approved a new option for the treatment of osteoporosis in postmenopausal women who have a high risk of fracture.

An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.

An advisory panel to the FDA has recommended the approval of a new treatment option for use in postmenopausal women with osteoporosis and high fracture risk.

The US Food and Drug Administration has approved a fifth indication for a human monoclonal antibody commonly used for the treatment of osteoporosis.

The US Food and Drug Administration has approved a fifth indication for a human monoclonal antibody commonly used for the treatment of osteoporosis.

The US Food and Drug Administration has approved a new treatment for osteoporosis for postmenopausal women at a high risk for fracture.